person · Reporting owner

Douglass Brian Robb

Disclosed activity across 1 company

Tapewire entity: 48950
SEC CIK: 0002104618

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
REPLIGEN CORPRGEN · Entity 486	CHIEF PRODUCT OFFICER	October 06, 2026	October 08, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

REPLIGEN CORP

Report date October 06, 2026 · Filed October 08, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	8,685	Reported balance After 2026-10-06 transaction · row 1 1 source row Row 1 · 2026-10-06 · Grant · Acquired 700 · Balance 8,685 F1: Mr. Douglass was awarded 700 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest in equal annual installments over a three-year period beginning on the first anniversary of the grant date. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $174.86 · Expires 2036-10-06	Direct	675	Reported balance After 2026-10-06 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-10-06 · Grant · Acquired 675 · Balance 675 F2: 225 shares will vest on each of October 6, 2027, October 6, 2028, and October 6, 2029.

Filing footnotes · ownership attribution and instrument terms

F1: Mr. Douglass was awarded 700 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest in equal annual installments over a three-year period beginning on the first anniversary of the grant date. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.

F2: 225 shares will vest on each of October 6, 2027, October 6, 2028, and October 6, 2029.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
October 06, 2026 Filed Oct 8, 2026 20:40 UTC	REPLIGEN CORP RGEN · Entity 486	GrantStock Option (Right to Buy) · Derivative	675	$0.00 Strike: $174.86	$0.00	Disclosure SEC source: 0001628280-26-065462 · wk-form4_1791492005.xml · derivative · entry 2 Douglass Brian Robb · CIK 0002104618 · CHIEF PRODUCT OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 675 Underlying: Common Stock · 675 shares Expires 2036-10-06 F2 · derivative.exercise_date: 225 shares will vest on each of October 6, 2027, October 6, 2028, and October 6, 2029. Read SEC document
October 06, 2026 Filed Oct 8, 2026 20:40 UTC	REPLIGEN CORP RGEN · Entity 486	GrantCommon Stock	700	$0.00	$0.00	Disclosure SEC source: 0001628280-26-065462 · wk-form4_1791492005.xml · nonDerivative · entry 1 Douglass Brian Robb · CIK 0002104618 · CHIEF PRODUCT OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,685 F1 · shares: Mr. Douglass was awarded 700 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest in equal annual installments over a three-year period beginning on the first anniversary of the grant date. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. Read SEC document
May 07, 2026 Filed May 8, 2026 18:39 UTC	REPLIGEN CORP RGEN · Entity 486	Tax withholdingCommon Stock	334	$126.43	$42,227.62	Disclosure SEC source: 0001193125-26-214265 · ownership.xml · nonDerivative · entry 1 Douglass Brian Robb · CIK 0002104618 · CHIEF PRODUCT OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,985 F1 · shares: Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations of the reporting person that arose upon the release of restricted stock units. Read SEC document
March 02, 2026 Filed Mar 3, 2026 17:48 UTC	REPLIGEN CORP RGEN · Entity 486	Tax withholdingCommon Stock	221	$124.97	$27,618.37	Disclosure SEC source: 0001193125-26-087447 · ownership.xml · nonDerivative · entry 1 Douglass Brian Robb · CIK 0002104618 · CHIEF PRODUCT OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,319 F1 · shares: Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations of the reporting person that arose upon the release of restricted stock units. Read SEC document
December 31, 2025 Filed Jan 12, 2026 21:32 UTC	REPLIGEN CORP RGEN · Entity 486	GrantStock Option (Right to Buy) · Derivative	2,143	$0.00 Strike: $163.86	$0.00	Disclosure SEC source: 0001193125-26-010470 · ownership.xml · derivative · entry 2 Douglass Brian Robb · CIK 0002104618 · CHIEF PRODUCT OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,143 Underlying: Common Stock · 2,143 shares Expires 2035-12-31 F2 · derivative.exercise_date: The shares will vest in substantially equal installments over a three-year period with each such vesting date occurring on the anniversary of the grant date. Read SEC document
December 31, 2025 Filed Jan 12, 2026 21:32 UTC	REPLIGEN CORP RGEN · Entity 486	GrantCommon Stock	2,288	$0.00	$0.00	Disclosure SEC source: 0001193125-26-010470 · ownership.xml · nonDerivative · entry 1 Douglass Brian Robb · CIK 0002104618 · CHIEF PRODUCT OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,540 F1 · shares: Mr. Douglass was awarded 2,288 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest in substantially equal annual instalments over a three-year period beginning on the first anniversary of the grant date. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.